Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 6 |
| List of Tables | 9 | 2 |
| List of Figures | 11 | 1 |
| Arthritis Therapeutics Market to 2018 - Introduction | 12 | 2 |
| Arthritis Therapeutics Market to 2018 - Market Overview | 14 | 6 |
| Introduction | 14 | 1 |
| Revenue Forecasts for the Global Arthritis Therapeutics Market | 15 | 1 |
| Revenue | 15 | 1 |
| Annual Cost of Treatment | 16 | 1 |
| Treatment Usage Patterns | 17 | 1 |
| Diseased Population | 18 | 1 |
| Treatment Seeking Population | 18 | 1 |
| Diagnosis Population | 18 | 1 |
| Prescription Population | 19 | 1 |
| Arthritis Therapeutics Market to 2018 - Therapeutic Landscape | 20 | 42 |
| Osteoarthritis Therapeutics Market | 20 | 1 |
| Introduction | 20 | 1 |
| Epidemiology | 21 | 1 |
| Symptoms | 21 | 1 |
| Diagnosis | 21 | 1 |
| Physical Examination | 21 | 1 |
| Diagnostic Imaging Techniques | 22 | 1 |
| X-ray | 22 | 1 |
| Computer Tomography Scan | 22 | 1 |
| Magnetic Resonance Imaging | 22 | 1 |
| Treatment | 22 | 1 |
| Non-Pharmacological Therapy | 23 | 1 |
| Exercise | 23 | 1 |
| Weight Loss | 23 | 1 |
| Pharmacological Therapy | 23 | 1 |
| Acetaminophen/Paracetamol | 23 | 1 |
| Non-Selective Non-Steroidal Anti-Inflammatory Drugs | 23 | 1 |
| Selective Non-Steroidal Anti-Inflammatory Drugs, COX-2 inhibitors | 23 | 1 |
| Narcotic Analgesics | 24 | 1 |
| Intra-articular Injections | 24 | 1 |
| Others | 24 | 1 |
| Surgical Treatment | 24 | 1 |
| Revenue | 25 | 1 |
| Annual Cost of Treatment | 26 | 1 |
| Treatment Usage Patterns | 27 | 1 |
| Diseased Population | 28 | 1 |
| Treatment Seeking Population | 28 | 1 |
| Diagnosis Population | 28 | 1 |
| Prescription Population | 28 | 1 |
| Marketed Products | 29 | 1 |
| Drivers and Barriers for the Osteoarthritis Therapeutics Market | 30 | 1 |
| Drivers for the Osteoarthritis Therapeutics Market | 30 | 1 |
| Increase in diseased population due to rise in elderly population (over 65 s population) | 30 | 1 |
| Obesity Epidemic | 30 | 1 |
| Barriers for the Osteoarthritis Therapeutics Market | 30 | 1 |
| Lack of disease modifying osteoarthritis drugs | 30 | 1 |
| Market dominated by generics | 31 | 1 |
| Increase Use of Alternative Therapies and Surgery | 31 | 1 |
| Opportunity and Unmet Need | 31 | 1 |
| Arthritis Therapeutics Market | 32 | 1 |
| Introduction | 32 | 1 |
| Epidemiology | 33 | 1 |
| Symptoms | 33 | 1 |
| Diagnosis | 34 | 1 |
| Physical Examination | 34 | 1 |
| Diagnostic Techniques | 34 | 1 |
| Blood Tests | 34 | 1 |
| Rheumatoid Factor (RF) Test: | 34 | 1 |
| Antinuclear Antibody It is also frequently observed in RA patients. | 34 | 1 |
| X-ray Testing | 35 | 1 |
| Treatment | 35 | 1 |
| Non-Pharmacological Therapy | 36 | 1 |
| Physical and Occupational Therapy | 36 | 1 |
| Psychological Therapy | 36 | 1 |
| Surgical Treatment | 36 | 1 |
| Pharmacological Therapy | 36 | 1 |
| Traditional Disease Modifying Anti-rheumatic Drugs | 36 | 1 |
| Biologic Disease Modifying Anti-rheumatic Drugs | 36 | 1 |
| Glucocortoids | 36 | 1 |
| Non Selective Non Steroidal Anti-Inflammatory Drugs | 37 | 1 |
| Revenue | 37 | 1 |
| Annual Cost of Treatment | 38 | 1 |
| Treatment Usage Patterns | 39 | 1 |
| Diseased Population | 40 | 1 |
| Treatment Seeking Population | 40 | 1 |
| Diagnosis Population | 40 | 1 |
| Prescription Population | 40 | 1 |
| Marketed products | 41 | 1 |
| Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market | 42 | 1 |
| Drivers for the Rheumatoid Arthritis Therapeutics Market | 42 | 1 |
| Increased number of new entrants such as high value biologics and oral disease modifying anti-rheumatic drugs | 42 | 1 |
| Increased uptake of prescription therapy and early use of disease modifying anti-rheumatic drugs | 42 | 1 |
| Increased Prevalence | 42 | 1 |
| Barriers for the Rheumatoid Arthritis Therapeutics Market | 42 | 1 |
| Alternative Therapies | 42 | 1 |
| Opportunity and Unmet Needs | 43 | 1 |
| Psoriatic Arthritis Therapeutics Market | 43 | 1 |
| Introduction | 43 | 1 |
| Epidemiology | 44 | 1 |
| Symptoms | 44 | 1 |
| Diagnosis | 44 | 1 |
| Physical Examination | 44 | 1 |
| Diagnostic Techniques | 44 | 1 |
| X-ray | 44 | 1 |
| Clinical Assessments | 44 | 1 |
| Treatment | 45 | 1 |
| Non-Pharmacological Therapy | 45 | 1 |
| Physical Exercise | 45 | 1 |
| Pharmacological Therapy | 45 | 1 |
| Non-Steroidal Anti-inflammatory Drugs | 45 | 1 |
| Conventional disease-modifying anti-rheumatic | 45 | 1 |
| Biologic Disease Modifying Anti-rheumatic Drugs | 46 | 1 |
| Surgery | 46 | 1 |
| Revenue | 46 | 1 |
| Annual Cost of Treatment | 47 | 1 |
| Treatment Usage Patterns | 48 | 1 |
| Diseased Population | 49 | 1 |
| Treatment Seeking Population | 49 | 1 |
| Diagnosis Population | 49 | 1 |
| Prescription Population | 50 | 1 |
| Marketed Products | 50 | 1 |
| Drivers and Barriers for the Psoriatic Arthritis Therapeutics Market | 51 | 1 |
| Drivers for the Psoriatic Arthritis Therapeutics Market | 51 | 1 |
| Increased safety and efficacy of new biologic disease modifying anti-rheumatic drugs | 51 | 1 |
| New guidelines issued to bring awareness to psoriatic arthritis patients | 51 | 1 |
| Barriers for the Psoriatic Arthritis Therapeutics Market | 51 | 1 |
| Austerity initiatives in Europe are causing reductions in healthcare spending | 51 | 1 |
| Opportunity and Unmet Needs | 51 | 1 |
| Introduction | 52 | 1 |
| Epidemiology | 52 | 1 |
| Symptoms | 53 | 1 |
| Diagnosis | 53 | 1 |
| Physical Examination | 53 | 1 |
| Diagnostic Techniques | 54 | 1 |
| Treatment | 54 | 1 |
| Non-Pharmacological Therapy | 54 | 1 |
| Physical Exercise | 54 | 1 |
| Weight Loss | 54 | 1 |
| Pharmacological Therapy | 55 | 1 |
| Analgesics/Paracetamol | 55 | 1 |
| Non-Steroidal Anti-inflammatory Drugs | 55 | 1 |
| Corticosteroids | 55 | 1 |
| Tumor necrosis factor inhibitors | 55 | 1 |
| Conventional Disease Modifying Anti-rheumatic Drugs | 55 | 1 |
| Surgery | 56 | 1 |
| Revenue | 56 | 1 |
| Annual Cost of Treatment | 57 | 1 |
| Treatment Usage Patterns | 58 | 1 |
| Diseased Population | 59 | 1 |
| Treatment Seeking Population | 59 | 1 |
| Diagnosis Population | 59 | 1 |
| Prescription Population | 59 | 1 |
| Marketed products | 60 | 1 |
| Drivers and Barriers for the Ankylosing Spondylitis Therapeutics Market | 60 | 1 |
| Drivers for the Ankylosing Spondylitis Therapeutics Market | 60 | 1 |
| Increase in patients on prescription | 60 | 1 |
| Increase use in biologic disease-modifying antirheumatic drugs | 60 | 1 |
| Barriers for the Ankylosing Spondylitis Therapeutics Market | 60 | 1 |
| Low Compliance Rate | 60 | 1 |
| No Diagnostic Tests for Early Diagnosis | 61 | 1 |
| Opportunity and Unmet Need | 61 | 1 |
| Arthritis Therapeutics Market to 2018 - Geographical Landscape | 62 | 14 |
| Revenue Analysis by Geography | 62 | 1 |
| The US | 63 | 1 |
| Revenue | 63 | 2 |
| Annual Cost of Treatment | 65 | 1 |
| Treatment Usage Patterns | 66 | 1 |
| Diseased Population | 67 | 1 |
| Treatment Seeking Population | 67 | 1 |
| Diagnosed Population | 67 | 1 |
| Prescription Population | 67 | 1 |
| Top Five European countries (UK, Germany, France, Italy and Spain) | 68 | 1 |
| Revenue | 68 | 1 |
| Annual Cost of Treatment | 69 | 1 |
| Treatment Usage Patterns | 70 | 1 |
| Diseased Population | 71 | 1 |
| Treatment Seeking Population | 71 | 1 |
| Diagnosed Population | 71 | 1 |
| Prescription Population | 71 | 1 |
| Japan | 72 | 1 |
| Revenue | 72 | 1 |
| Annual Cost of Treatment | 73 | 1 |
| Treatment Usage Patterns | 74 | 1 |
| Diseased Population | 75 | 1 |
| Treatment Seeking Population | 75 | 1 |
| Diagnosed Population | 75 | 1 |
| Prescription Population | 75 | 1 |
| Arthritis Therapeutics Market to 2018 - Product Pipeline Analysis | 76 | 28 |
| Introduction | 78 | 1 |
| Research and Development Pipeline Osteoarthritis | 78 | 1 |
| Discovery | 79 | 1 |
| Preclinical | 80 | 1 |
| Phase I | 80 | 1 |
| Phase II | 81 | 1 |
| Phase III | 82 | 1 |
| NDA Filed | 82 | 1 |
| Introduction | 83 | 1 |
| Research and Development Pipeline Rheumatoid Arthritis | 83 | 1 |
| Discovery | 84 | 1 |
| Preclinical | 85 | 4 |
| Phase I | 89 | 1 |
| Phase II | 90 | 3 |
| Phase III | 93 | 1 |
| NDA filed | 94 | 1 |
| Introduction | 95 | 1 |
| Research and Development Pipeline Psoriasis Arthritis | 95 | 1 |
| Introduction | 96 | 1 |
| Research and Development Pipeline Ankylosing Spondylitis | 96 | 2 |
| Profiles of Promising Drugs in the Pipeline | 98 | 1 |
| Tofacitinib (CP-690550) | 98 | 1 |
| Overview | 98 | 1 |
| Clinical Study Details | 98 | 1 |
| Safety and Efficacy | 98 | 1 |
| Ofatumumab | 99 | 1 |
| Overview | 99 | 1 |
| Clinical Study Details | 99 | 1 |
| Safety and Efficacy | 99 | 1 |
| Secukinumab (AIN457) | 99 | 1 |
| Overview | 99 | 1 |
| Clinical Study Details | 99 | 1 |
| Safety and Efficacy | 99 | 1 |
| Fostamatinib (R788) | 100 | 1 |
| Overview | 100 | 1 |
| Clinical Study Details | 100 | 1 |
| Safety and Efficacy | 100 | 1 |
| LY2127399 (Tabalumab) | 101 | 1 |
| Overview | 101 | 1 |
| Clinical Study Details | 101 | 1 |
| Safety and Efficacy | 101 | 1 |
| REGN88 (SAR153191) | 102 | 1 |
| Overview | 102 | 1 |
| Clinical Study Details | 102 | 1 |
| Safety and Efficacy | 102 | 1 |
| LT-NS001 | 103 | 1 |
| Overview | 103 | 1 |
| Clinical Study Details | 103 | 1 |
| Safety and Efficacy | 103 | 1 |
| Arthritis Therapeutics Market to 2018 - Competitive Landscape | 104 | 9 |
| Market Share Analysis | 104 | 1 |
| Major Players | 104 | 1 |
| Competitive Profile | 105 | 1 |
| Roche | 105 | 1 |
| Overview | 105 | 1 |
| Product Portfolio | 105 | 1 |
| SWOT Profile | 106 | 1 |
| Johnson &Johnson | 107 | 1 |
| Overview | 107 | 1 |
| Product Portfolio | 107 | 1 |
| SWOT Profile | 107 | 1 |
| Pfizer | 108 | 1 |
| Overview | 108 | 1 |
| Product Portfolio | 108 | 1 |
| SWOT Profile | 109 | 1 |
| Abbott Laboratories | 110 | 1 |
| Overview | 110 | 1 |
